BRIEF-Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
Reuters2026/09/23 11:04Roivant Sciences Ltd ROIV.O:
ROIVANT ANNOUNCES TOPLINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF IMVT-1402 IN CUTANEOUS LUPUS ERYTHEMATOSUS
ROIVANT SCIENCES - IMVT-1402 STUDY IN CLE DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
ROIVANT SCIENCES - IMMUNOVANT TO STOP DEVELOPMENT OF IMVT-1402 IN CLE
ROIVANT SCIENCES - IMVT-1402 DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
ROIVANT SCIENCES - ALL OTHER CLINICAL DEVELOPMENT TIMELINES REMAIN ON TRACK
Source text: ID:nGNX559XzF
Further company coverage: ROIV.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270
Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Crypto prices
More
